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ABSTRACT
Introduction: Verruca vulgaris, also known as
common warts, are benign skin growths caused
by infection of the skin by human
papillomavirus. Warts are common in both
childhood and adulthood and are spread by
direct contact or autoinoculation. Treatment
options vary from locally destructive methods
to immuno-modulatory therapy. Common
warts are often resistant to treatment. Though
many remedies exist, there is no consensus
therapy backed by randomized-controlled
clinical trials that are FDA approved for the
treatment of verruca vulgaris. We describe here
the results of a small, randomized,
double-blind, vehicle-controlled Phase II
clinical trial with a novel topical agent for the
treatment of common warts.
Methods: Twenty-one patients aged 8 years and
older were enrolled in this single-center,
randomized, double-blind, vehicle-controlled
Phase II clinical trial to assess the efficacy,
safety and tolerability of twice-daily
application of a novel 2% topical
povidone–iodine solution in a dimethyl
sulfoxide vehicle for 12 weeks duration.
Patients were block randomized into two
groups consisting of 14 patients in the active
arm and 7 patients in the vehicle only arm. All
patients were evaluated at baseline, week 4, 8
and 12 and the results compared for overall
Global Aesthetic Improvement Scale (GAIS)
improvement.
Results: There were a total of 21 patients
included in the study. Sustained improvement
in the GAIS scale was observed at the final week
12 exam visit in 77% of subjects in the
treatment arm and 33% of patients in the
control arm. There were no serious safety or
tolerability issues reported.
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Conclusion: Twice-daily topical
povidone–iodine solution in the novel vehicle
employed for this study is an effective, safe and
easy-to-use treatment for common warts.
Further study of this agent in expanded Phase
II and Phase III clinical trials is warranted.
Funding: ALC Therapeutics LLC.




Verruca vulgaris, also known as common warts,
are benign skin growths caused by a viral
infection of the skin. It is a worldwide
infection that affects 7–12% of the population
[1]. The cause of the condition is the human
papilloma virus (HPV), which is a
double-stranded, circular, supercoiled DNA
virus enclosed in an icosahedral capsid and
comprising 72 capsomers. There are more than
70 genotypes of HPV, and the genotypes are
referenced by numbers. The common wart is
most frequently caused by genotypes HPV-1, 2,
4, 27 and 57. Warts are prevalent in both
childhood and adulthood and are spread by
direct contact or autoinoculation. Verruca
vulgaris typically occurs on the back of fingers
or toes and on the knees, but they may occur
anywhere on the skin or mucosal surface.
Treatment is recommended for patients with
extensive, spreading, or symptomatic warts [2].
Many patients feel the condition is socially
stigmatizing. Treatment methods that are
commonly employed include topical agents,
intralesional injections, systemic agents,
cryotherapy, laser, electrodessication and
surgical excision, although common warts can
be resistant to treatment [3, 4]. Clinical
evidence favoring one therapeutic route over
another is limited [5].
Iodophor preparations are commonly used
in all medical specialties for skin antisepsis prior
to percutaneous procedures and surgery [6].
Primarily iodophors work by delivering active
molecular iodine to target tissues through
enhanced aqueous solubilization. The most
commonly used iodophor is povidone–iodine.
Povidone–iodine kills microorganisms
including bacteria, viruses, yeasts, molds, fungi
and protozoa [7, 8]. In this randomized,
double-blind, vehicle-controlled study, we
utilized a novel 2% PVP-I solution in a topical
dimethyl sulfoxide vehicle twice daily for the
treatment of common warts.
METHODS
The trial protocol and informed consent
documents were approved by an Institutional
Review Board experienced in both adult and
pediatric studies. All procedures followed were
in accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Twenty-one patients aged
8 years and older were included in this
single-center, randomized, double-blind,
vehicle-controlled phase-2 proof-of-concept
study. The examiner determined the diagnosis
of common warts clinically. Informed consent
was obtained from all participants or
participants’ guardian if less than age of
consent after explaining in detail the purpose
and procedure of the treatment. Healthy
individuals were deemed eligible for
participation if they had at least one but not
exceeding ten common warts. Warts located in
the following areas did not qualify patients for
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inclusion in the study: the eye area (including
eyelids), lips, mouth cavity, nasal cavity, inner
ear, palms of the hands (including periungual
area), soles of the feet (including periungual
area), or the anogenital area. Those patients
with prior treatment to the wart within the last
30 days were excluded, as were
immunosuppressed and pregnant populations.
Fourteen patients were allocated into the active
arm (2% PVP-I in vehicle solution twice daily)
and seven patients were allocated into the
vehicle-control solution arm twice daily, for a
duration of 12 weeks in each arm. Both active
drug and vehicle solution were made via a
licensed GMP compounding pharmacy and
matched for both color and consistency.
Patients were evaluated at baseline, weeks 4, 8,
and 12 with paring done at each visit. Global
Aesthetic Improvement Scale (GAIS) scores were
used as the benchmark for efficacy analysis. The
GAIS is a 5-point scale rating global esthetic
improvement in appearance, compared to
pretreatment, as judged by the investigator.
GAIS scoring for individual warts at each visit
was as follows: very much improved (?3), much
improved (?2), improved (?1), no change (0)
and worse (-1). Improvement was defined as a
decrease in the diameter and thickness of the
wart before paring was performed.
RESULTS
Twenty-one patients were enrolled in this
study. Of the fourteen patients enrolled in the
active arm, thirteen completed the study. For
patients randomized into the active arm of
treatment, 10/13 (77%) demonstrated sustained
improvement in the GAIS scale score, defined as
an overall positive score derived from the
summation of individual assessments at the
Week 4, 8 and 12 visits. Sustained improvement
was defined as wart showing decreased diameter
and thickness from baseline. In the 3/13
patients in the active arm that did not show
sustained improvement, the patients’ warts
remained stable in size, and there were no
additional warts at the sites observed. Each of
the patients was followed through week 12 and
there were no recurrences of warts that cleared
before the 12-week time period. Subjective
tolerability was assessed using a grading scale
for stinging, burning and itching as reported by
the patient. Zero patients reported these,
respectively. Adverse side effects such as
erythema, scaling and dryness were assessed by
the examiner, with 2/13 (15%) patients
demonstrating mild dryness.
Of the seven patients enrolled in the
vehicle-controlled arm, six patients completed
the study. 2/6 (33%) warts showed sustained
improvement in the GAIS scale score, 2/6 (33%)
showed a worsening of the GAIS scale score and
2/6 (33%) showed no change from baseline.
Subjective tolerability was assessed using a
grading scale for stinging, burning and itching
as reported by the patient. Zero patients
reported these, respectively. Adverse side
effects such as erythema, scaling and dryness
were assessed by the examiner, with 1/6 (17%)
patients demonstrating mild dryness.
DISCUSSION
Though various treatments are currently in use
for common warts, no single therapy has
emerged as effective in all cases. Purely
destructive methods, such as liquid nitrogen
(cryotherapy) and salicylic acid formulations
either alone or in combination are the most
commonly utilized methods [9, 10].
Immuno-modulating agents are also
commonly employed off-label, such as oral
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cimetidine, injectable candida antigen,
levamisole and imiquimod [11–13]. These
agents are believed to up-regulate a Type IV
hypersensitivity reaction but are not effective in
all patients [14]. Intralesional bleomycin and
5-fluorouracil are painful to inject and carry risk
of significant side effects such as necrosis [15,
16]. Duration of treatment is often lengthy
regardless of modality, requiring several months
of treatment and numerous painful procedures
in an office setting. There is scant evidence that
any single therapy is useful in every clinical
situation [17].
Low-dose (i.e., less than the commonly used
10%) PVP-I solutions have not been well studied
in dermatology. Most dermatological literature
describes skin antisepsis with 10%
povidone–iodine [18]. There have been some
anecdotal reports of efficacy in the treatment of
onychomycosis including one case report using
a similar formulation to that under study in this
report [19]. There have been several studies of
low-dose PVP-I employed in otology and
ophthalmology, though none have described
any novel vehicle formulations that are capable
of penetrating an intact skin or mucosal surface
[20–22]. PVP-I solutions have shown excellent
in vitro efficacy against enveloped model
viruses as well as some non-enveloped human
viruses, e.g., adenovirus and polyomavirus [23].
We report here the first randomized, controlled
human clinical trials with low-dose PVP-I in a
vehicle optimized for skin penetration.
The use of PVP-I at relatively lower
concentrations than commonly employed in
surgical antisepsis is new in dermatology. In
particular, the development of novel
formulations useful when administered in
multiple doses has gained recent interest for
chronic, difficult-to-treat infections in both skin
and nails. These new agents based on PVP-I are
useful for all microorganisms including bacteria,
viruses, yeasts, molds, fungi and protozoa [24].
Their utility against HPV infections derives from
its non-specific mechanism of action. PVP-I
poisons electron transport, inhibits cellular
respiration, destabilizes membranes, inhibits
protein synthesis and denatures nucleic acids in
the HPV virus and in virus-infected host cells.
Resistance is very unlikely to develop given its
non-specific means of inhibiting viral
replication.
The study had some limitations that should
be addressed if any further studies are planned.
Most notably the patient sample size was
inadequate to provide a base for meaningful
statistical analysis, though a trend towards
efficacy and a clear indication of safety was
demonstrated. The solution formulation used in
the trial requires 1–2 min to dry completely,
making it difficult for optimal compliance in
the pediatric population. We suspect the
contact time of the drug to skin was limited
due to this issue, and have already developed a
gel formulation for use in future studies.
CONCLUSION
This novel PVP-I formulation appears to be an
effective, safe and well-tolerated treatment of
common warts in both children and adults.
Further study in expanded Phase II/III trials are
warranted to develop new therapies for these
common, difficult-to-treat infections.
Additional study with a gel formulation may
elaborate a variety of effective therapies for
difficult-to-treat skin and skin structure
infections.
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